This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avenue Therapeutics' Pain Drug Gets Complete Response Letter
by Zacks Equity Research
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall
by Zacks Equity Research
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
Why Is Mallinckrodt (MNK) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges
by Kinjel Shah
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Mallinckrodt (MNK) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Mallinckrodt (MNK) delivered earnings and revenue surprises of 51.20% and 12.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Mallinckrodt (MNK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Growth Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 24th
Uncertainty Looms Large Over Generic Drug Industry Players
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.
Are Options Traders Betting on a Big Move in Cameco Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin
by Zacks Equity Research
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
FDA Advisory Committee to Review Mallinckrodt'sTerlipressin
by Zacks Equity Research
Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.
Heron's Pain Management Drug Gets Complete Response Letter
by Zacks Equity Research
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns
Why Is Mallinckrodt (MNK) Down 5.8% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Mallinckrodt (MNK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Mallinckrodt (MNK) Q1 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Mallinckrodt (MNK) declines on sales miss in the first quarter and a challenging outlook for the remainder of the year despite reporting an earnings beat.
Mallinckrodt (MNK) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.